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Abstract 36 
Dopamine D2/D3 receptor availability at rest and its association with individual pain perception was 37 
investigated using the [
11
C] raclopride PET-method in 24 female Fibromyalgia (FMS) participants 38 
with (FMS+, N=11) and without (FMS-, N=13) comorbid depression and in 17 healthy women. 39 
Thermal pain thresholds (TPT) and pain responses were assessed outside the scanner. We compared 40 
the discriminative capacity, i.e. the individual’s capacity to discriminate between lower and higher 41 
pain intensities and the response criterion, i.e. the subject’s tendency to report pain during noxious 42 
stimulation due to psychological factors. [
11
C] raclopride binding potential (BP), defined as the ratio of 43 
specifically bound to non-displaceable radioligand at equilibrium (BPND) was used as measure of 44 
D2/D3 receptor availability. We found significant group effects of BPND in striatal regions (left ventral 45 
striatum, left caudate nucleus and left nucleus accumbens) between FMS+ and FMS- compared to 46 
healthy subjects. Correlational analysis showed negative associations between TPT and D2/D3 47 
receptor availability in the left caudate nucleus in FMS-, between TPT and D2/D3 receptor availability 48 
in the right caudate nucleus in FMS + and positive associations between TPT and D2/D3 receptor 49 
availability in the left putamen and right caudate nucleus in healthy controls. The response criterion 50 
was positively associated with D2/D3 receptor availability in the right nucleus accumbens in FMS – 51 
and negatively with D2/D3 receptor availability in the left caudate nucleus in healthy controls. Finally, 52 
no significant associations between D2/D3 receptor availability and discriminative capacity in any of 53 
the groups or regions was determined. These findings provide further support for a disruption of 54 
dopaminergic neurotransmission in FMS and implicate DA as important neurochemical moderator of 55 
differences in pain perception in FMS patients with and without co-morbid depression.  56 
 57 
Number of words = 283 58 
  59 
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Introduction 60 
Fibromyalgia syndrome (FMS) is an idiopathic, diffuse soft-tissue pain syndrome with unclear 61 
pathophysiology (Wolfe, 1990). Major depressive disorder (MDD) is the most frequent psychiatric 62 
comorbidity in FMS (Fietta, Fietta, & Manganelli, 2007). A growing awareness of the role of 63 
mesolimbic dopamine (DA) in pain perception, specifically in anti-nociception, has emerged in recent 64 
years (Hagelberg et al., 2004; Jarcho, Mayer, Jiang, Feier, & London, 2012; Wood, 2008). Although 65 
its precise function in nociceptive processes is only partially understood, DA regulation has been 66 
shown to be disrupted in MDD and chronic pain (Epstein et al., 2006; Wood, 2008). Several Positron 67 
Emission Tomography (PET)-  studies demonstrated altered post-synaptic striatal DA 68 
neurotransmission in chronic neuropathic pain syndromes including burning mouth, and atypical facial 69 
pain, (Hagelberg, Forssell, Aalto, et al., 2003; Hagelberg, Forssell, Rinne, et al., 2003; Wood, 70 
Schweinhardt, et al., 2007) while an alteration of presynaptic DA transmission was evidenced in FMS 71 
(Wood, Patterson, et al., 2007). Results of in vivo DA studies in MDD brought contradictory results 72 
(recently reviewed by (Savitz & Drevets, 2013) ). When differences were found they indicated a 73 
reduced DA function in MDD that was however influenced by medication. However, postsynpatic DA 74 
function has not been investigated so far in FMS and the role of depression in the DA changes 75 
observed in chronic pain is not clear. 76 
Moreover a positive correlation between individual pain sensitivity and striatal baseline raclopride 77 
binding was observed in healthy volunteers (Hagelberg et al., 2002; Pertovaara et al., 2004; Scott, 78 
Heitzeg, Koeppe, Stohler, & Zubieta, 2006). Pain sensitivity can be determined using the Signal 79 
Detection Theory (SDT) that distinguishes two measures: the discriminative capacity, a measure of 80 
neurosensory sensitivity, reflecting the subject’s ability to discriminate between two stimuli of similar, 81 
yet distinct, intensities. A low discriminative capacity is associated with relative insensitivity to 82 
noxious stimulation and indicates an attenuation of neural activity in the sensory system (Clark & 83 
Mehl, 1971). The response criterion is independent from discriminability and locates the person’s 84 
overall tendency to report pain; a high value indicates a stoical attitude (Clark & Mehl, 1971). The 85 
response criterion and thermal pain threshold (TPT) were shown to be inversely correlated with the 86 
D2/D3 Binding Potential (BP) in the right putamen in healthy volunteers, whereas the sensory 87 
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discriminative capacity was not significantly correlated with the D2/D3 BP in any striatal region 88 
(Pertovaara et al., 2004). The association between measures of pain sensitivity with D2/D3 binding 89 
has not been yet examined in chronic pain conditions.  90 
Here, we investigated the D2/D3 receptor availability at rest between FMS participants with (FMS+) 91 
and without (FMS –) comorbid depression compared to healthy controls using the [11C] raclopride 92 
PET method to measure postsynaptic striatal D2/D3 receptor availability. We expected FMS patients 93 
to show reduced [
11
C] raclopride binding (measures as the ratio of specifically bound to non-94 
displaceable radioligand at equilibrium (BPND) in striatal regions compared to healthy controls, 95 
reflecting a decreased postsynaptic availability of D2/D3 receptors in these patients as already 96 
described at the presynaptic levels (Wood, Patterson, et al., 2007) and in agreement with findings for 97 
neuropathic pain conditions (Hagelberg, Forssell, Aalto, et al., 2003; Hagelberg, Forssell, Rinne, et al., 98 
2003). We expected the reduction to be more pronounced in FMS+ patients than FMS- patients. 99 
Additionally, we aimed to test the association between pain sensitivity and striatal D2/D3 receptor 100 
availability with regard to the role of comorbid MDD. We expected FMS patients to have decreased 101 
thermal pain thresholds (TPT) and thermal pain tolerance (TOL), correlated to altered D2/D3 receptor 102 
availability, but for pain responses to show no correlation with BPND in striatal regions. Together, we 103 
believe that such evidence would indicate that the dopaminergic influence on pain sensitivity is 104 
impaired in FMS.  105 
 106 
Experimental procedures 107 
Subjects 108 
Given the predominance of women in FMS (Wolfe, Ross, Anderson, Russell, & Hebert, 1995) and to 109 
reduce the heterogeneity of study samples, we decided to only include women in this study. A total of 110 
24 female FMS patients were compared to 17 age- and gender-matched healthy control subjects. 111 
Among the FMS patients 11 subjects were diagnosed with comorbid MDD. All FMS+ patients had the 112 
onset of MDD subsequent to the FMS diagnosis. A description of clinical and demographic data 113 
parameters for the FMS patients is provided in Table 1. FMS patients fulfilling the American College 114 
of Rheumatology (ACR) classification criteria for Fibromyalgia (Wolfe et al., 1990) with decreased 115 
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pressure pain thresholds at a minimum of 11 of 18 specific tender points, located in 9 paired regions of 116 
the body, were recruited from the Division of Rheumatology at the University Hospital Zurich. They 117 
were recruited through flyers in medical practices, advertisements in newspapers, and advertisements 118 
on websites associated with FMS. Controls were recruited through flyers on bulletin boards in public 119 
places. Current and/or chronic medical conditions, current and/or lifetime psychiatric diagnoses, acute 120 
or chronic pain and medication other than oral contraceptives were exclusion criteria for the controls. 121 
All FMS patients had their FMS diagnosis confirmed by an experienced rheumatologist (HS) through 122 
clinical examination, including measurements of pain thresholds at tender points using a digital 123 
dolorimeter (LD 100 NRS, AC Engineering Basel, Switzerland). FMS subjects had a mean pain 124 
duration of 13.46 years (SD=11.98), and a mean number of 16 tender points (SD=3.66). FMS subjects 125 
were allowed to continue their SSRI (selective serotonin-reuptake inhibitors), TCA (tricyclic 126 
antidepressants) and NSAID (non-steroidal anti-inflammatory drugs) medication during the study. A 127 
total number of 12 FMS patients were taking antidepressant medication either for pain or depressive 128 
symptoms. The use of opioids, neuroleptics, antiepileptics, and lithium was an exclusion criterion. All 129 
subjects were tested for comorbid psychiatric disorders using the SCID (Structured Clinical Interview 130 
for DSM-IV (First, 2002)). This instrument was also used to diagnose MDD in the FMS group. The 131 
severity of depression was measured with the Beck Depression Inventory (BDI) , German version 132 
(Hautzinger, Bailer, Worall, & Keller, 1995), and the Montgomery Åsberg Depression Scale 133 
(MADRS) (Montgomery & Asberg, 1979). Anxiety was assessed using the State-Trait Anxiety 134 
Inventory (STAI) (Laux, Glanzmann, Schaffner, & Spielberger, 1981). All participants were screened 135 
for general MRI and PET exclusion criteria, pregnancy (pregnancy test on the day of scanning), and 136 
breast-feeding. They were required to sign an informed consent which explained the procedures of the 137 
study prior to information and testing. The study was approved by the Ethical Committee of the 138 
Canton Zurich and the Swiss Federal Department of Health in accordance with the current version of 139 
the declaration of Helsinki and the Swiss regulatory requirements. 140 
 141 
PET image acquisition 142 
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[11C] raclopride is an established in vivo method for estimating the availability of D2/D3 receptors in 143 
the brain. The D2/D3 receptor antagonist [
11
C] raclopride was produced on site according to Good 144 
Manufacturing Practice (GMP) guidelines. PET scans were acquired using a PET/CT scanner with an 145 
axial field of view of 15.3 cm in 3D mode (Discovery STE, GE Healthcare, Waukesha, WI, USA) at 146 
the Department of Nuclear Medicine at the University Hospital Zurich. PET data were reconstructed 147 
using filtered back projectioned segmented attenuation correction, for which a low dose CT scan was 148 
acquired.  149 
On the day of the PET study, subjects were asked to eat a well-balanced meal before the PET scanning 150 
and not to consume too many liquids to ensure personal comfort during the scans. The PET 151 
measurement took place in the same time frame (Monday afternoon from 3 pm to 5pm) for all 152 
participants. [
11
C] raclopride was injected as a slow bolus (260+/-20 MBq). Mean specific activity of 153 
the tracer at time point of injection was (M=121.75GBq/µmol, SD=43.63). Dynamic scanning was 154 
initiated at the time of tracer injection and continued for 60 min (31 frames of 4x15sec, 8x30sec, 155 
9x60sec, 2x180sec, 8x300sec, total 60 min duration). Image data from 40-50 minutes were averaged 156 
and exported for further processing in the PMOD software (Version 3.2, PMOD Technologies, Zurich, 157 
Switzerland).  158 
 159 
Magnetic resonance imaging 160 
Each subject received a high-resolution T1 weighted magnetic resonance scan (3D fast-field echo 161 
scans with 160 slices, 1mm isotropic resolution, TR= 18ms, TE= 10ms, flip angle= 30°) on a Philips 162 
Ingenia Scanner for co-registration with PET images. All images were checked for structural 163 
abnormalities and lesions by a clinical neuroradiologist. 164 
 165 
Determination of thermal pain threshold (TPT), pain tolerance threshold (TOL), and pain 166 
modulation 167 
Standardized pain testing procedures were conducted by the same investigator on the same day as the 168 
PET scanning with each subject in a separate session in a quiet room with constant ambient 169 
temperature. Thermal pain threshold (TPT) and thermal pain tolerance (TOL) were determined using a 170 
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method of limits procedure (Hansen, Hopf, & Treede, 1996). Thermal cutaneous pain response was 171 
measured by delivering heat stimuli to the thenar of the non-dominant hand with a 27-mm-diameter 172 
thermal contact thermode (CHEPS, Medoc Ltd, Ramat Yishai, Israel). The CHEPS thermode has a 173 
heating rate of 70°C/s and a cooling rate of 40°C/s. The same heating and cooling rate was applied 174 
during the whole procedure. The CHEPS thermode has a subject response device that immediately 175 
records the temperature once activated, and resets the thermode to the adaptation temperature in 176 
preparation for the next trial. The area of the stimulus surface was 5.7. cm
2
. TPT and TOL estimation 177 
was based on five thermal stimuli starting at 32°C and rising linearly at a rate of 1°C/s until it was 178 
stopped either by a button press or when the maximum temperature of 52°C was reached. To 179 
determine TPT, subjects were asked to press the button on the response device when they experienced 180 
pain for the first time. To examine TOL, subjects were asked to push the response button when the 181 
sensation on their hand became intolerable or unbearable. The experimental paradigm for the pain 182 
modulation was adapted and slightly modified from the study of (Pertovaara et al., 2004). Heat 183 
stimulation started at 34.5°C and the temperature was increased linearly at a rate of 3°C/s to one of the 184 
six predetermined temperatures (45.8, 46.3, 46.8, 47.3, 47.8, and 48.3°C) for a duration of 4s, after 185 
which the stimulus temperature returned to baseline. The interval between successive stimulations was 186 
15s. Each stimulus temperature was applied eight times and the order the stimuli were presented was 187 
randomized across subjects. After presentation of each stimulus, the subject was asked to rate the 188 
sensation evoked by the stimulus using a numerical rating scale ranging from 0 = no pain at all to 10 = 189 
strongest pain imaginable. Before the actual testing sessions all subjects went through a brief training 190 
session in which they were introduced to the experimental condition. The area of stimulation was 191 
slightly varied by moving the thermode either to the left or right side for each trial to prevent 192 
sensitization.  193 
 194 
Determination of the subject’s discriminative capacity and response criterion 195 
We chose the same components as (Pertovaara et al., 2004) derived from the Signal Detection Theory 196 
(SDT) to determine the individual response characteristics to pain. Discriminative Capacity was 197 
computed by the trapezoidal rule as the area below the Receiver Operating Characteristics (ROC) 198 
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Curve which is generated by cumulating probabilities of hits and false alarms for each response 199 
elicited by the stimulus temperatures of 46.8° vs. 47.3° using PASW Statistics 21.0 (SPSS Inc., 200 
Chicago, Ill, USA). The exact description of the calculations of the response criterion is provided in 201 
detail elsewhere (Pertovaara et al., 2004). Briefly, the criterion was defined as the rating scale criterion 202 
where half the responses (to both stimulus intensities in each pair) are divided into higher response 203 
categories and the other half into lower response categories. The response criterion was defined as 204 
C=0.5(ZSN+ZN). Within the calculation, the probability of rating a stimulus of 47.3° as painful (rating 205 
categories 6-10 pooled together) was converted to a Z score (ZSN) as described by Gescheider (1997, 206 
pp.122-123 and Table A). The probability of rating a stimulus of 46.8° as non-painful (rating 207 
categories 1-5 pooled together) was also converted to a Z score (ZN).  208 
 209 
Data analysis 210 
ROI analysis 211 
All PET emission scans were reconstructed using 3D filtered back projection including a 6mm FWHM 212 
Hanning filter, producing an estimated final FWHM (full width at half maximum) of 10-12mm. 213 
Corrections for subject motion during the 60 min PET acquisition were performed with a mutual 214 
information registration of each image frame to a standard frame (0-8min after injection) before 215 
attenuation correction. Based on the calculated motion, the transmission images were re-sliced and 216 
projected for final attenuation correction, reconstruction and realignment. The realigned frames were 217 
summed to generate an image that was co-registered with the corresponding MRI image using PMOD 218 
software Version 3.2 (PMOD Technologies Ltd, Zurich, Switzerland). This was performed for the first 219 
8 minutes of scanning, during which the radiotracer distribution was most sensitive to cerebral blood 220 
flow (CBF), and thus for the cortical outlines to be sufficiently evident in order to guide image co-221 
registration. The PET frames were summed and co-registered with the corresponding magnetic 222 
resonance image, and both images were transformed linearly into standardized stereotaxic space using 223 
the Montreal Neurological Institute template. Mean tissue radioactivity concentrations were extracted 224 
using MRI based regions of interest (ROI’s), defined on a template MRI image using PMOD software 225 
in the anteroventral striatum, putamen, nucleus accumbens, caudate nucleus and cerebellum after 226 
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Drevets et al. (Drevets et al., 2001). Each individual MRI was registered to the template brain and the 227 
ROI’s were repositioned as needed to accommodate for individual differences in anatomy. The 228 
anatomical accuracy and symmetry of each set of individual ROI’s was verified by a neuroscientist 229 
familiar with striatal anatomy (CMS). These ROI’s were then back-transformed into the subject’s 230 
native MRI space and applied to the co-registered PET images (example in Figure 1). Simplified 231 
reference tissue model (SRTM) (Lammertsma & Hume, 1996) was used for derivation of binding 232 
potential (BP) using the cerebellum as reference region. The outcome measure was binding potential, 233 
defined as the ratio of specifically bound to non-displaceable radioligand at equilibrium (BPND) . BPND 234 
can also be described as BPND = fND * (Bmax/KD) where Bmax is the concentration of D2/3 receptors, 235 
KD is the inverse of the affinity of the radiotracer for the receptor, and fND is the free fraction in the 236 
nonspecific distribution volume of the brain. For each region, the BPND for patients and controls were 237 
compared with those for FMS+ and FMS- patients and controls. Relationships between BPND and the 238 
pain thresholds and measures were analyzed with the Pearson product-moment correlation coefficient. 239 
A two-tailed probability value of p<0.05 was chosen as the level of significance. Since age is known 240 
to affect D2/D3 receptor BP, this factor was included in the analysis.  241 
 242 
Figure 1: ROI’s placement. Transverse view Cau: Nucleus caudatus; NA: Nucleus accumbens; Pu: 243 
Putamen 244 
 245 
Analysis of behavioral data 246 
PASW Statistics 21.0 software (SPSS Inc., Chicago, Ill, USA) was used for statistical analysis. Data 247 
distribution was tested with the Kolmogorov-Smirnov test and by observing data histograms. The 248 
results of normally distributed data are presented as mean +/- standard deviations. One way analysis of 249 
Feldfunktion geändert
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variance (ANOVA) was used to assess differences in D2/D3 receptor availability between groups 250 
(healthy, FMS-, FMS+) for each region of interest. Since age is known to affect D2/D3 receptor BP, 251 
this factor was included in the analysis. Additional analyses included FMS duration, antidepressant 252 
 medication and BDI as factors. The difference between groups for experimental pain ratings (pain 253 
threshold, discriminative capacity, and response criterion) of each group was tested using independent 254 
samples t-tests and one-way ANOVA followed by post-hoc tests, where appropriate. P<0.05 was 255 
considered to represent a statistically significant difference. 256 
Associations between D2/D3 receptor availability and psychophysical results (pain threshold, 257 
discriminative capacity, response criterion) were determined using Pearson’s coefficient of correlation. 258 
P<0.05 was considered as statistically significant.  259 
  260 
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Results 261 
ROI Analyses 262 
Mean BPND are summarized in Table 2. Analysis of postsynaptic D2/D3 receptor availability, 263 
measured by [
11
C] raclopride, demonstrated a significant group effects between healthy subjects, FMS- 264 
and FMS+ patients in the left ventral striatum (F(2.33)=5.3, p=0.01), left caudate nucleus (F(2.33)= 265 
3.8, p=0.03), and the left nucleus accumbens (F(2.33)= 4.1, p=0.03) after controlling for the effect of 266 
age (see Table 3). The covariate age was significantly related to the BPND in the left ventral striatum 267 
(F(1.33)=19.9, p=0.01). Simple contrasts revealed significantly less BPND in the left caudate nucleus 268 
and left nucleus accumbens in FMS+ patients compared to healthy controls (p=0.01, resp. p=0.02) and 269 
significantly less BPND in the left ventral striatum in FMS- than FMS+ patients (p=0.02). In additional 270 
analyses with the covariates BDI, FMS duration and antidepressant medication no significant 271 
correlations were found with BPND in any striatal regions (p>0.1).  272 
 273 
Experimental pain ratings (TPT, TOL, response criterion, discriminative capacity) 274 
Table 3 represents the mean values of all experimental pain ratings. 275 
An independent samples t-test was conducted to compare TPT and TOL between all FMS patients 276 
(n=24) and healthy controls (n=17). FMS patients showed a significantly lower TPT (m=41.1, 277 
SD=4.5) compared to healthy subjects (m=45.0, SD=4.4; t(39)=2.8, p=0.01). Also the TOL was 278 
significantly lower in FMS patients (m=44.7, SD=3.7) compared to healthy subjects (m=47.7, SD=3.7; 279 
t(39)=2.5, p=0.02). One-way ANOVA considering 3 groups of subjects showed significant effects for 280 
TPT (F(2,38)=4.34, p=0.02) and TOL (F(2,38)=3.7, p=0.03). A post-hoc Gabriel test indicated that 281 
FMS+ patients reported a significantly lower TPT (p<0.02) and TOL (p<0.03) than healthy subjects. 282 
The FMS- group did not significantly differ from the other two groups. The index of response bias 283 
(response criterion) and the discriminative capacity did not differ significantly between the three 284 
groups (F (2.35)=0.61, p>0.94, resp. F(2.16)=1.18, p>0.33 for discriminative capacity). The response 285 
criterion was not significantly correlated with TPT (healthy subjects p>0.6, FMS- p>0.07 and FMS+ 286 
p>0.9) or TOL (healthy subjects p>0.3, FMS- p>0.3, FMS+ p>0.09). Discriminative capacity was not 287 
associated with TPT (healthy subjects p>0.3, FMS- p>0.4, FMS+ p>0.2 ) or TOL (healthy subjects 288 
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p>0.4, FMS- p>0.7, FMS+ p>0.2) in any of the groups. FMS duration, antidepressant medication or 289 
BDI were not significantly correlated to TOL or TPT (p>0.1). 290 
 291 
Correlation of D2/D3 receptor availability with pain responses 292 
Thermal Pain Threshold (TPT) 293 
In FMS+ patients, striatal D2/D3 receptor availability in the right nucleus caudate was significantly 294 
correlated with TPT (r= 0.65, p=0.03) (see Figure 2). In FMS- patients, striatal D2/D3 receptor 295 
availability in the left caudate nucleus was significantly correlated with TPT (r=0.66, p=0.02), (see 296 
Figure 3). 297 
In healthy subjects, striatal D2/D3 receptor availability in the left putamen (r=0.56, p=0.01) and right 298 
caudate nucleus (r=0.513, p=0.05) were significantly associated with TPT (see Figure 4).  299 
 300 
Thermal Pain Tolerance (TOL) 301 
No significant correlations between striatal D2/D3 receptor availability and TOL were found in any of 302 
the three groups (p>0.2). 303 
 304 
Response criterion 305 
Healthy subjects showed a significant correlation of the response criterion with the D2/D3 receptor 306 
availability in the left caudate nucleus (r=-0.645, p=0.001) (see Figure 5). FMS– showed a significant 307 
correlation of the response criterion with the D2/D3 receptor availability in the right nucleus 308 
accumbens (r=0.67, p=0.03) (see Figure 6). No significant correlations of the response criterion with 309 
the D2/D3 receptor availability in any striatal region could be determined for FMS+. 310 
 311 
Discriminative capacity 312 
The index of the subject’s discriminative capacity, the area under the ROC curve, varied over a wide 313 
range between the subjects and did not differ significantly between the three groups (F(1.38)=2.1, 314 
p=0.15). Correlations of the discriminative capacity with the D2 receptor availability were not 315 
significant (p>0.17) in any of the three groups.  316 
317 
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Discussion 318 
The major innovation of the present study was that it examined the link between striatal D2/D3 319 
receptor availability and individual pain perception in FMS patients, both with and without comorbid 320 
MDD, compared to healthy subjects using the [
11
C] raclopride PET method. To our knowledge, this is 321 
the first study investigating the link between striatal D2/D3 receptor availability and individual pain 322 
responses in FMS that differentiated between individuals with and without depression. 323 
In line with our expectations, we found significant group differences in BPND in striatal regions (left 324 
ventral striatum, left caudate nucleus and left nucleus accumbens) between FMS+ and FMS- compared 325 
to healthy subjects. Furthermore, the correlational analyses showed different associations between 326 
striatal D2 receptor availability and thermal pain thresholds that differentiated between FMS patients 327 
with and without depression and healthy controls. We found negative associations of D2/D3 receptor 328 
availability in the left caudate nucleus in FMS- and right caudate nucleus in FMS+. In healthy 329 
subjects, the thermal pain threshold correlated positively with D2/D3 receptor availability in the left 330 
putamen and right caudate nucleus. Further, for the response criterion, we found a positive association 331 
with D2/D3 receptor availability in the right nucleus accumbens in FMS- patients and a negative 332 
correlation of the response criterion with D2/D3 receptor availability in the left caudate nucleus in 333 
healthy controls. Finally, no correlations between D2/D3 receptor availability and discriminative 334 
capacity in any of the groups or regions could be determined. Taken together, these findings provide 335 
further support for a disruption of dopaminergic neurotransmission in FMS and implicate DA as 336 
important neurochemical moderator of differences in pain perception in FMS patients with and 337 
without co-morbid depression. Our findings are similar to previous studies which have demonstrated 338 
reductions in 6-
18
F fluoro-L-DOPA uptake in dopaminergic centers of the midbrain (i.e. ventral 339 
tegmental area and substantia nigra) in FMS (Wood, Patterson, et al., 2007), and lower raclopride BP 340 
in FMS patients than healthy controls in all functional sub-regions of the striatum during non-painful 341 
saline infusion (Wood, Schweinhardt, et al., 2007). However, it is not entirely clear if this result 342 
reflects decreased DA receptor density or a greater release of DA in response to non-painful saline 343 
infusion and is therefore not directly comparable to our experimental paradigm. No study so far has 344 
investigated the baseline DA changes at the post-synaptic level in Fibromyalgia (i.e. in the absence of 345 
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noxious stimuli). Furthermore, several Positron Emission Tomography (PET) studies evidenced an 346 
increased D2 receptor availability in chronic neuropathic pain conditions such as burning mouth 347 
syndrome (Hagelberg, Forssell, Rinne, et al., 2003) or atypical facial pain (Hagelberg, Forssell, Aalto, 348 
et al., 2003) suggesting a contribution of reduced dopaminergic inhibition to the chronic pain 349 
condition. Our results indicating the opposite changes suggest that FMS patients differ from 350 
neuropathic pain patients at a neurochemical level. Interestingly, we found significantly less BPND 351 
raclopride binding in FMS patients with depression compared to those without  depression in the left 352 
ventral striatum, a region that has been shown to be associated with emotional processing of pain 353 
(Scott et al., 2006). This suggests that FMS patients with and without depression can also be 354 
distinguished on a neurochemical level which might also influence treatment options. FMS patients 355 
with comorbid depression showed significantly less [
11
C] raclopride binding in the left caudate nucleus 356 
and nucleus accumbens compared to healthy controls, suggesting more free DA receptors or 357 
dysfunctional receptors in these patients.  358 
The Sensory Detection Theory analysis showed that Fibromyalgia patients with and without 359 
depression did not set a higher criterion for reporting pain and did also not differ in terms of 360 
discriminative capacity from our healthy controls. Consistent with previous studies, the thermal pain 361 
tolerance and thresholds of the FMS patients in our study differed from healthy controls, further 362 
confirming the findings of greater responsiveness to pain in FMS induced by a wide variety of 363 
stimulus modalities (Klauenberg et al., 2008). However, we found no difference in terms of thermal 364 
pain threshold and tolerance between FMS patients with and without comorbid MDD, which was also 365 
described in another study comparing FMS patients with and without comorbid MDD (de Souza, 366 
Goffaux, et al., 2009). The results from the correlation analysis between D2/D3 receptor availability 367 
and psychophysical results in Fibromyalgia patients with and without depression support a disrupted 368 
pain modulatory role of striatal D2 receptors in FMS. Our results suggest a potential link between 369 
D2/D3 receptor availability and pain perception due to psychological factors in FMS which differ 370 
however between patients with and without comorbid depression. In Fibromyalgia patients without 371 
depression, D2/D3 receptor availability in the right nucleus accumbens was positively associated with 372 
the criterion to report pain, but not in FMS patients without comorbid depression. Since the response 373 
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criterion is a measure for psychological aspects of pain, the pain sensitivity in Fibromyalgia patients 374 
without depression appears to be determined mainly by a dopaminergic influence on psychological 375 
factors that in turn influence the subject’s tendency to report pain rather than by physiological factors. 376 
In line with this finding psychological factors have been shown to have an important role in variability 377 
of pain ratings between subjects (Clark & Mehl, 1971). On the other hand cognitive and affective 378 
variables frequently occurring in FMS such as depression, anxiety or pain-related anxiety (Lachaine, 379 
Beauchemin, & Landry, 2010; Rutledge, Mouttapa, & Wood, 2009) were related to increased pain 380 
report and responses. Also personality traits associated with FMS (Malin & Littlejohn, 2012) such as 381 
detachment, anxiety, and novelty seeking, were related to D2/D3 receptor availability (Breier et al., 382 
1998; Farde, Gustavsson, & Jonsson, 1997; Suhara et al., 2001) and increased pain report (Farde et al., 383 
1997). This matches the assumption that emotional and psychological processes may play a 384 
particularly important role in promoting pain in these patients  and that affect may contribute to pain in 385 
FMS (Staud, Price, Robinson, & Vierck, 2004). In addition, D2 receptor-mediated neurotransmission 386 
in the ventral system involving the nucleus accumbens, has been shown to be associated with 387 
emotional processing of pain (Scott et al., 2006). Consistent with the possibility that psychological 388 
factors contribute to pain in FMS via DA transmission, it has recently been proposed that DA could 389 
play a role in modulating the salience of a pain stimulus (Becker et al., 2013), fostering coping 390 
responses, rather than having direct anti-nociceptive effects. This mediating role of DA might 391 
eventually explain why we found associations between striatal D2/D3 receptor availability in regions 392 
associated with emotional modulation of pain and psychophysical measures of emotional/attitudinal 393 
aspects of pain in our FMS patients. In Fibromyalgia patients with depression, D2/D3 receptor 394 
availability in the right caudate was negatively associated with thermal pain threshold, but not with the 395 
response criterion or discriminative capacity. Evidence showing that D2 receptor-mediated 396 
neurotransmission in the dorsal caudate and putamen is associated with subjective ratings of sensory 397 
and affective qualities of pain (Scott et al., 2006), suggests that D2/D3 receptor availability in the right 398 
caudate of Fibromyalgia patients with depression influences non-sensory mechanisms underlying the 399 
pain response rather than actual pain sensitivity. These results are in line with a previous fMRI study 400 
which suggested that the presence of depression had no effect on the sensory-discriminative 401 
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processing of pain stimulation but had a selective effect on brain regions that process the affective-402 
motivational dimension of pain (Giesecke et al., 2005). Furthermore, this result and the fact that FMS 403 
patients with depression conveyed a lower pain threshold than the other subject groups, support the 404 
idea of a more pronounced deficit in pain inhibition in FMS with comorbid depressive symptoms (de 405 
Souza, Potvin, Goffaux, Charest, & Marchand, 2009), suggesting that depression could influence pain 406 
perception in FMS via DA. Our findings in Fibromyalgia patients with and without depression are not 407 
consistent with previous reports in healthy subjects where the pain threshold and the response criterion 408 
were inversely correlated with the D2/D3 BP in the human striatum (right putamen) (Pertovaara et al., 409 
2004). The same study showed that the discriminative capacity is not a critical factor responsible for 410 
the association of pain responses with D2/D3 BP in healthy subjects (Pertovaara et al., 2004). This 411 
result is in line with our findings both in healthy subjects and Fibromyalgia patients. In accordance 412 
with our hypothesis, we found significant positive correlations between the thermal pain threshold and 413 
D2/D3 receptor availability in striatal regions including the left putamen, and the right caudate nucleus 414 
in healthy subjects. This result however, contradicts previous findings that reported direct correlations 415 
between striatal D2/D3 receptors and pain thresholds in the right putamen  (Hagelberg et al., 2002; 416 
Pertovaara et al., 2004). Lateralization differences in the DA system are well documented and an 417 
influence of gender on lateralization of the function of the DA system has previously been shown 418 
(Martin-Soelch et al., 2011). The deviation from the previous finding could therefore be explained by 419 
the inclusion of women in our study while the other studies included only men (Pertovaara et al., 420 
2004). Furthermore, some pain-related phenomena such as pain threshold have been shown to occur 421 
with a laterality bias (Lugo, Isturiz, Lara, Garcia, & Eblen-Zaijur, 2002). Moreover, associations 422 
between the D2 binding capacity and conditioned pain modulation, which reflects the capacity of the 423 
brain to inhibit and to modulate incoming pain signals, have been reported in the left putamen 424 
(Hagelberg et al., 2002).  425 
Several previous PET studies also using [
11
C] raclopride showed increased D2 receptor availability in 426 
chronic neuropathic pain conditions such as burning mouth syndrome (Hagelberg, Forssell, Rinne, et 427 
al., 2003) or atypical facial pain (Hagelberg, Forssell, Aalto, et al., 2003). An overlapping 428 
pathophysiology between FMS and neuropathic pain has been suggested due to shared clinical 429 
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features such as paresthesias, hyperalgesia and allodynia (Maletic & Raison, 2009), but our results 430 
indicate that striatal D2/D3 receptor availability in FMS patients with and without depressive 431 
symptoms are not impaired in the same way as in chronic neuropathic pain conditions. 432 
Abnormal sensory thresholds were also evidenced in neuropathic pain such as burning mouth 433 
syndrome or trigeminal non-idiopathic neuropathic pain (de Siqueira, Teixeira, & de Siqueira, 2013). 434 
Abnormal sensory findings are considered important features in the classification of neuropathic pain 435 
according to the International Association for the study of pain (IASP). Therefore, the observation of 436 
abnormal sensory thresholds and the disrupted modulatory role of striatal D2/D3 receptors in pain 437 
processing in FMS could be added to other neuronal changes observed in these patients (for instance 438 
impaired small fiber function in FMS) (Uceyler et al., 2013), contradicting the opinion that FMS is a 439 
pure somatization disorder without demonstrable abnormality.  440 
 441 
Some limitations merit attention. This study did not allow for differentiation between D2/D3 receptor 442 
density or intrasynaptic dopamine concentration and the interpretation of underlying neuronal factors 443 
should be treated with caution. Prior work indicates that [11C] raclopride values from the bolus method 444 
are almost identical to binding values generated by a bolus-infusion method (Carson, 2000), in which 445 
DA release can be indirectly measured for the same subjects. Although SPM analysis of PET ligand 446 
studies is a viable alternative to ROI analysis, especially for the exploration of changes without a 447 
priori region definitions, requirements of the analysis include transformation of the PET data to 448 
standard anatomical space, smoothing of the data and quantitative normalization to account for global 449 
effects. In a small cohort as in our study, these processes may reduce the sensitivity to subtle changes 450 
in raclopride binding. Standardization of the basal ganglia anatomy for SPM analysis is a known 451 
challenge (in comparison to cortical anatomy). Therefore, our individual anatomy MR-based VOI 452 
analysis may be considered to better account for individual basal ganglia anatomy and improve the 453 
sensitivity of our PET measurements. Further, we did not correct for multiple comparisons, and 454 
therefore it remains possible that our results would not survive methods for the correction of multiple 455 
testing. Another limitation is that we did not include chronic neuropathic pain patients to control for 456 
similarities or differences between FMS and neuropathic pain. A further limitation is that the painful 457 
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stimuli were not adapted to the different pain thresholds of FMS patients and controls thus making the 458 
comparison of the evoked processes difficult. Further, we did not control for phases of menstrual cycle 459 
in our participants. However, the majority of the participants were postmenopausal (N=19, see Table 460 
1). Finally, DA receptor binding results as well as the individual responses to pain may have been 461 
biased by the patients’ medication, which possibly influenced the testing procedures, including slower 462 
reaction times and anti-nociceptive effects of antidepressants (N=12). Nevertheless, we found 463 
significant differences between FMS patients and healthy subjects with regard to the estimation of 464 
pain thresholds, and a previous study (Klauenberg et al., 2008) found no significant group difference 465 
concerning SSRI medication regarding all pain thresholds. It is however possible that the lack of 466 
differences in D2/D3 receptor availability may be related to the medication.  467 
 468 
Conclusion 469 
To our knowledge, this is the first report on the association between D2/D3 receptor availability and 470 
pain perception in FMS, distinguishing between FMS patients with and without comorbid depression. 471 
Additionally, in comparison to previous studies in this field, our study included a relatively large 472 
sample of patients. In conclusion, our data suggest that there are differences in D2/D3 receptor 473 
availability at rest between FMS patients with depression and without depression compared to healthy 474 
subjects. This study presents novel results suggesting that the association between D2/D3 receptor 475 
availability and pain perception differs between healthy subjects and patients with Fibromyalgia. 476 
Furthermore, this association also differed between FMS patients with and without depression, 477 
suggesting that depression could influence pain perception in FMS. Our results suggest that alterations 478 
in the dopaminergic system appear to be linked to pain sensitivity in FMS patients. Striatal D2/D3 479 
receptor availability in FMS patients with and without depression is associated with psychological 480 
aspects of pain rather than the discriminative capacity of the sensory system mediating pain. However, 481 
the exact mechanisms have yet to be elucidated and similarities with chronic neuropathic pain patients 482 
with regard to the modulatory function of DA in pain should be further explored. These findings 483 
contribute to the understanding of the function of the dopaminergic system in central pain processing 484 
in healthy individuals and in patients with FMS.  485 
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